Paul Sagan | Investor Relations |
Glenn Mattes | President and Chief Executive Officer |
Kirk Coleman | Chief Financial Officer |
Dale Christensen | Director, Clinical Development |
Chris Cano | Chief Operating Officer |
Bill Williams | Professor, University of Texas, Austin |
Jonathan Aschoff | ROTH |
Daniel Carlson | Tailwinds Research |
William Morrison | National Securities |
Doug Russell | Brown Harris Stevens |
Good afternoon, ladies and gentlemen and welcome to the TFF Pharmaceuticals’ Third Quarter 2020 Financial Results. I would now like to turn the call over to your host, Mr. Paul Sagan of TFF Pharmaceuticals, Investor Relations.
You may begin your conference.
Thank you very much, operator.